Yahoo · Oct 31, 2026
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
NYSE · LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
$1,417.54
Up+$43.84 (+3.19%)
Updated Oct 31, 2026, 9:05 AM
SID Score
7.0/10
Composite research score
Smart Money
44/100
Neutral
- Market cap
- 906.5B
- P/E ratio
- 49.16
- Dividend yield
- 0.55%
- 52-week range
- $850.51 – $1,449.68
- Volume
- 5.25M
- Avg. volume
- 3.8M
Price performance · LLY
LLY price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LLY closed at $1,417.54 after 21 trading sessions, up 24.04% for the selected period.
- Last close
- $1,417.54
- Period change
- +24.04%
- Period low
- $1,142.85
- Period high
- $1,417.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1,428.83 | $1,449.68 | $1,408.36 | $1,417.54 | 5.25M |
| Oct 29, 2026 | $1,332.73 | $1,408.38 | $1,330.00 | $1,373.70 | 4.37M |
| Oct 28, 2026 | $1,268.55 | $1,299.43 | $1,260.34 | $1,288.30 | 2.06M |
| Oct 27, 2026 | $1,273.50 | $1,297.92 | $1,272.0703 | $1,281.91 | 1.85M |
| Oct 26, 2026 | $1,286.39 | $1,296.90 | $1,273.7293 | $1,279.14 | 2.11M |
| Oct 23, 2026 | $1,304.15 | $1,307.9199 | $1,257.62 | $1,273.46 | 2.28M |
| Oct 22, 2026 | $1,281.76 | $1,321.21 | $1,275.10 | $1,306.69 | 2.66M |
| Oct 21, 2026 | $1,266.905 | $1,279.28 | $1,261.08 | $1,270.75 | 1.88M |
| Oct 20, 2026 | $1,263.50 | $1,311.75 | $1,260.17 | $1,283.66 | 2.97M |
| Oct 19, 2026 | $1,243.39 | $1,259.75 | $1,239.10 | $1,240.34 | 1.96M |
| Oct 16, 2026 | $1,256.00 | $1,274.56 | $1,251.25 | $1,257.03 | 2.41M |
| Oct 15, 2026 | $1,235.04 | $1,275.88 | $1,230.66 | $1,251.61 | 3.76M |
| Oct 14, 2026 | $1,177.87 | $1,216.714 | $1,174.24 | $1,208.74 | 3.17M |
| Oct 13, 2026 | $1,190.70 | $1,193.30 | $1,158.405 | $1,166.51 | 1.84M |
| Oct 12, 2026 | $1,181.24 | $1,188.70 | $1,172.805 | $1,182.62 | 1.25M |
| Oct 9, 2026 | $1,153.56 | $1,179.82 | $1,151.67 | $1,179.27 | 1.39M |
| Oct 8, 2026 | $1,183.50 | $1,186.0903 | $1,131.21 | $1,169.60 | 3.09M |
| Oct 7, 2026 | $1,173.62 | $1,206.63 | $1,166.00 | $1,188.72 | 2.31M |
| Oct 6, 2026 | $1,147.15 | $1,177.065 | $1,139.98 | $1,157.49 | 2.13M |
| Oct 5, 2026 | $1,150.76 | $1,165.73 | $1,139.495 | $1,143.12 | 1.98M |
| Oct 2, 2026 | $1,153.82 | $1,164.9155 | $1,136.66 | $1,142.85 | 2.05M |
Latest LLY news
The latest Smart Investors Daily articles mentioning LLY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LLY research
Overview
Company profile and research snapshot.
Company profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $1,055.92
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Outperform | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 30, 2026 | Wells Fargo | Overweight | — |
| Oct 30, 2026 | Morgan Stanley | Overweight | — |
| Oct 30, 2026 | Scotiabank | Sector Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call
Eli Lilly and Company (NYSE:LLY) raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound incretin medicines and continued growth across international markets. Chair and CEO Dave Ricks said
Yahoo · Oct 30, 2026
Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 Competition
Eli Lilly trial data showing retatrutide outperforming Ozempic has sharpened the competitive focus on Novo Nordisk (NYSE:NVO), just as the Danish drugmaker outlines longer term 2030 goals. Novo Nordisk’s share price has reacted sharply to this rising GLP-1 competition, with a 1-day share price return of 2.20% and 30-day share price return of 5.51%. These sit against a year-to-date share price decline of 23.65% and a 3-year total shareholder return down 56.69%, which signals fading momentum...
Yahoo · Oct 30, 2026
OmniAb, Inc. Q3 2026 Earnings Call Summary
Moby summary of OmniAb, Inc.'s Q3 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company Stock Performance
Eli Lilly and Company shares closed at $1,417.54, reflecting a single-session decline of 1.66% per SID market data. Despite the daily pullback, LLY has delivered substantial gains across longer timeframes, rising 23.28% over the past month, 26.41% over three months, and 33.22% year-over-year according to Massive/Polygon data. The stock currently trades well above key moving averages, sitting 18.4% above its 50-day moving average of $1,197.14 and 30.2% above its 200-day moving average of $1,088.35. The 14-day relative strength index registers at 79.9, placing LLY firmly in overbought territory and indicating sustained buying pressure in recent sessions. The company carries a beta of 0.369, reflecting significantly lower volatility relative to the broader market. Eli Lilly's market capitalization stands at approximately $906.5 billion, with average daily trading volume of roughly 3.8 million shares per SID market data.
Eli Lilly and Company Valuation Analysis
Eli Lilly and Company trades at a price-to-earnings ratio of 49.16, a premium valuation relative to the broader Healthcare sector, according to SID market data. The PEG ratio stands at 1.47, suggesting the elevated earnings multiple is partially supported by the company's projected growth trajectory, though it remains above the commonly referenced fair-value threshold of 1.0. The price-to-book ratio registers at 38.04, reflecting significant market premium over the company's net asset value per SEC filings. This elevated book value multiple is consistent with investor expectations surrounding Eli Lilly's pharmaceutical pipeline and revenue-generating franchises. The company currently offers a dividend yield of approximately 0.59%, a modest payout that reflects management's prioritization of reinvestment in research and development. Collectively, these metrics indicate that the market is pricing in substantial future earnings growth to justify current valuation levels across multiple fundamental measures.
Smart Money Activity for LLY
Eli Lilly and Company registers a composite smart money score of 44 out of 100 with a neutral overall signal, according to SID market data. Institutional positioning is the strongest component, scoring a maximum 25 out of 25, indicating robust ownership and accumulation by large fund managers per 13F institutional filings. Insider activity scores 7.1 out of 25, with 16 insider transactions recorded over the past 90 days comprising 9 purchases and 7 sales according to SEC Form 4 filings. The slight bias toward insider buying suggests measured confidence among company executives, though the overall insider score remains modest. Dark pool activity scores 9.0 out of 25, indicating moderate levels of off-exchange institutional trading. Congressional trading activity registers at just 3.2 out of 25, reflecting minimal disclosed trading by members of Congress. The divergence between strong institutional conviction and subdued scores in other smart money categories produces the neutral composite reading, warranting continued monitoring of insider and dark pool trends.
Eli Lilly and Company Earnings Outlook
Eli Lilly and Company has established a consistent pattern of exceeding Wall Street expectations across its three most recently reported quarters, according to company earnings reports. The most recent quarter delivered earnings per share of $8.55 against an estimate of $6.85, representing a positive surprise of $1.70. The preceding quarter produced an even larger beat, with actual EPS of $8.38 versus the $6.01 consensus estimate, a $2.37 upside surprise. The quarter before that posted EPS of $7.48 against a $6.36 estimate, exceeding expectations by $1.12. Across these three quarters, Eli Lilly averaged a positive earnings surprise of approximately $1.73 per share. The upcoming quarter carries an analyst consensus estimate of $8.84 EPS per analyst estimates, which would represent a sequential increase if achieved. The sustained magnitude of earnings beats suggests analysts may still be underestimating the company's revenue momentum and operational leverage.
Wall Street Analyst Ratings for LLY
Wall Street analysts maintain uniformly bullish coverage on Eli Lilly and Company, with all five most recent ratings reaffirming positive stances according to Wall Street analyst reports issued on October 30, 2026. RBC Capital reiterated its Outperform rating, while Truist Securities maintained a Buy recommendation. Wells Fargo and Morgan Stanley both reaffirmed Overweight ratings, and Scotiabank held its Sector Outperform designation per SID consensus data. Notably, none of these five analysts changed their prior ratings, indicating stable conviction rather than upgrades driven by new catalysts. The absence of any Hold, Underweight, or Sell ratings among recent coverage actions underscores broad institutional consensus around LLY's growth profile, driven primarily by its GLP-1 receptor agonist franchise. The simultaneous reaffirmation by five major firms on the same date likely coincides with the company's latest earnings release, reflecting immediate post-results assessment. The consensus remains decisively positive with no dissenting views among tracked analysts.
